Compound 4b can be considered as a lead compound or candidate in the treatment of neurodegenerative diseases because of its remarkable NO-inhibitory activity, potent inhibition against the release of TNF-α and IL-6 and possibly good permeability through the blood–brain barrier. This evidence concerns the gene IL6 and neurodegenerative disease.